BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10419880)

  • 1. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.
    Rook AH; Wood GS; Yoo EK; Elenitsas R; Kao DM; Sherman ML; Witmer WK; Rockwell KA; Shane RB; Lessin SR; Vonderheid EC
    Blood; 1999 Aug; 94(3):902-8. PubMed ID: 10419880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role for interleukin-12 therapy of cutaneous T cell lymphoma.
    Rook AH; Zaki MH; Wysocka M; Wood GS; Duvic M; Showe LC; Foss F; Shapiro M; Kuzel TM; Olsen EA; Vonderheid EC; Laliberte R; Sherman ML
    Ann N Y Acad Sci; 2001 Sep; 941():177-84. PubMed ID: 11594571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
    Duvic M; Sherman ML; Wood GS; Kuzel TM; Olsen E; Foss F; Laliberté RJ; Ryan JL; Zonno K; Rook AH
    J Am Acad Dermatol; 2006 Nov; 55(5):807-13. PubMed ID: 17052486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
    J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
    Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
    J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin-homing CD8+ T lymphocytes show preferential growth in vitro and suppress CD4+ T-cell proliferation in patients with early stages of cutaneous T-cell lymphoma.
    Thestrup-Pedersen K; Parhar R; Wu K; Bertilsson PA; Meyer B; Abu-Amero S; Hainau B; Aleisa A; Alfadley A; Hamadah I; Alajlan A; Al-Hussein K; Al-Mohanna F
    Acta Derm Venereol; 2007; 87(2):118-26. PubMed ID: 17340017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
    Cebon J; Jäger E; Shackleton MJ; Gibbs P; Davis ID; Hopkins W; Gibbs S; Chen Q; Karbach J; Jackson H; MacGregor DP; Sturrock S; Vaughan H; Maraskovsky E; Neumann A; Hoffman E; Sherman ML; Knuth A
    Cancer Immun; 2003 Jul; 3():7. PubMed ID: 12862418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous CD8+ cytotoxic T-cell lymphoma involving the epidermis and subcutis in a young child.
    Wang L; Gao T; Wang G
    J Cutan Pathol; 2015 Apr; 42(4):271-5. PubMed ID: 25458991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8(+) granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency.
    Gammon B; Robson A; Deonizio J; Arkin L; Guitart J
    J Am Acad Dermatol; 2014 Sep; 71(3):555-60. PubMed ID: 24813299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
    Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
    Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.
    Rook AH; Kuzel TM; Olsen EA
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1435-48, ix. PubMed ID: 14710894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
    Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
    Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
    J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity.
    Seo N; Tokura Y; Matsumoto K; Furukawa F; Takigawa M
    Clin Exp Immunol; 1998 Jun; 112(3):403-9. PubMed ID: 9649208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
    Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
    Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
    Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
    Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.